| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 30 | 2023 | 5767 | 2.090 |
Why?
|
| Receptors, Androgen | 6 | 2020 | 878 | 1.570 |
Why?
|
| MicroRNAs | 8 | 2023 | 2947 | 0.910 |
Why?
|
| Androgen Antagonists | 6 | 2016 | 411 | 0.700 |
Why?
|
| Adipocytes, White | 2 | 2016 | 34 | 0.670 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 2 | 2016 | 93 | 0.640 |
Why?
|
| Prostate | 5 | 2023 | 1088 | 0.640 |
Why?
|
| Brachytherapy | 6 | 2020 | 977 | 0.610 |
Why?
|
| Pyruvic Acid | 1 | 2018 | 133 | 0.600 |
Why?
|
| Energy Metabolism | 4 | 2019 | 992 | 0.570 |
Why?
|
| Argonaute Proteins | 1 | 2016 | 40 | 0.560 |
Why?
|
| Memory | 4 | 2005 | 429 | 0.550 |
Why?
|
| Lipid Metabolism | 2 | 2016 | 483 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2016 | 287 | 0.520 |
Why?
|
| Adipose Tissue, Brown | 1 | 2015 | 112 | 0.510 |
Why?
|
| Mitochondria | 2 | 2018 | 1282 | 0.490 |
Why?
|
| Prostate-Specific Antigen | 6 | 2023 | 993 | 0.490 |
Why?
|
| PPAR gamma | 1 | 2015 | 229 | 0.490 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2014 | 34 | 0.480 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 130 | 0.480 |
Why?
|
| Drosophila | 4 | 2004 | 839 | 0.470 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2016 | 362 | 0.470 |
Why?
|
| Promoter Regions, Genetic | 5 | 2016 | 3101 | 0.460 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 487 | 0.450 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2012 | 840 | 0.440 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 622 | 0.430 |
Why?
|
| Uveal Neoplasms | 1 | 2014 | 176 | 0.420 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2020 | 336 | 0.420 |
Why?
|
| Tamoxifen | 2 | 2012 | 876 | 0.390 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1910 | 0.390 |
Why?
|
| Palladium | 2 | 2020 | 56 | 0.370 |
Why?
|
| Homeostasis | 1 | 2015 | 950 | 0.370 |
Why?
|
| Adenocarcinoma | 5 | 2023 | 7789 | 0.360 |
Why?
|
| Radioisotopes | 2 | 2020 | 177 | 0.350 |
Why?
|
| Genes, BRCA1 | 1 | 2012 | 387 | 0.350 |
Why?
|
| Drosophila melanogaster | 2 | 2005 | 829 | 0.330 |
Why?
|
| DNA Damage | 1 | 2016 | 1954 | 0.310 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2018 | 2104 | 0.300 |
Why?
|
| Vaginal Neoplasms | 1 | 2008 | 152 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2023 | 8873 | 0.300 |
Why?
|
| Drosophila Proteins | 3 | 2003 | 858 | 0.290 |
Why?
|
| Breast Neoplasms | 11 | 2023 | 15694 | 0.280 |
Why?
|
| Neuronal Plasticity | 2 | 2005 | 304 | 0.280 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2005 | 22 | 0.270 |
Why?
|
| DNA Methylation | 2 | 2014 | 2669 | 0.270 |
Why?
|
| Gene Targeting | 2 | 2004 | 292 | 0.260 |
Why?
|
| Humans | 59 | 2023 | 261506 | 0.260 |
Why?
|
| Male | 35 | 2023 | 123000 | 0.260 |
Why?
|
| Biomarkers | 2 | 2016 | 5047 | 0.260 |
Why?
|
| Radiation Injuries | 5 | 2020 | 1411 | 0.260 |
Why?
|
| Smell | 1 | 2005 | 125 | 0.250 |
Why?
|
| Quality of Life | 4 | 2023 | 4532 | 0.240 |
Why?
|
| Melanoma | 2 | 2014 | 5317 | 0.240 |
Why?
|
| Adenylyl Cyclases | 1 | 2003 | 87 | 0.240 |
Why?
|
| Neural Pathways | 1 | 2005 | 298 | 0.230 |
Why?
|
| Mushroom Bodies | 1 | 2003 | 48 | 0.230 |
Why?
|
| Cell Proliferation | 6 | 2023 | 7226 | 0.230 |
Why?
|
| Neoplasm Grading | 5 | 2019 | 1742 | 0.230 |
Why?
|
| Prostatectomy | 3 | 2019 | 962 | 0.230 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2018 | 425 | 0.220 |
Why?
|
| Cell Line, Tumor | 8 | 2023 | 14551 | 0.210 |
Why?
|
| Learning | 1 | 2005 | 403 | 0.210 |
Why?
|
| Prosencephalon | 1 | 2001 | 43 | 0.210 |
Why?
|
| Rectum | 3 | 2020 | 467 | 0.200 |
Why?
|
| RNA Interference | 2 | 2016 | 1408 | 0.200 |
Why?
|
| Insulin Resistance | 2 | 2018 | 731 | 0.200 |
Why?
|
| Odorants | 1 | 2001 | 73 | 0.190 |
Why?
|
| Adipocytes | 2 | 2013 | 305 | 0.190 |
Why?
|
| Urinary Bladder | 3 | 2019 | 575 | 0.190 |
Why?
|
| Heat-Shock Proteins | 2 | 2014 | 311 | 0.190 |
Why?
|
| Animals | 20 | 2019 | 59536 | 0.190 |
Why?
|
| Urination Disorders | 2 | 2018 | 61 | 0.190 |
Why?
|
| Urethral Diseases | 1 | 2020 | 36 | 0.190 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 4053 | 0.180 |
Why?
|
| Genome-Wide Association Study | 1 | 2008 | 2265 | 0.180 |
Why?
|
| Antineoplastic Protocols | 1 | 2020 | 33 | 0.180 |
Why?
|
| Radiotherapy Dosage | 8 | 2020 | 3842 | 0.180 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 43 | 0.180 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 86 | 0.180 |
Why?
|
| Lipogenesis | 1 | 2020 | 76 | 0.180 |
Why?
|
| Aldehyde Oxidase | 1 | 2019 | 8 | 0.180 |
Why?
|
| Citric Acid | 1 | 2020 | 54 | 0.180 |
Why?
|
| Multigene Family | 2 | 2013 | 425 | 0.180 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 2216 | 0.180 |
Why?
|
| Transgenes | 4 | 2013 | 557 | 0.170 |
Why?
|
| Aged | 24 | 2023 | 70117 | 0.170 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2018 | 44 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 253 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 4757 | 0.160 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 73 | 0.160 |
Why?
|
| Rectal Diseases | 1 | 2018 | 55 | 0.160 |
Why?
|
| Mutation | 3 | 2014 | 15179 | 0.160 |
Why?
|
| Synaptic Transmission | 1 | 2001 | 443 | 0.160 |
Why?
|
| Research Design | 1 | 2005 | 1544 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 245 | 0.160 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2014 | 10035 | 0.160 |
Why?
|
| Genome, Human | 3 | 2014 | 1869 | 0.150 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 92 | 0.150 |
Why?
|
| Transcription Factors | 5 | 2016 | 5270 | 0.150 |
Why?
|
| Biological Transport | 1 | 2018 | 597 | 0.150 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.150 |
Why?
|
| Glutamine | 1 | 2018 | 299 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 291 | 0.150 |
Why?
|
| Hexosamines | 1 | 2016 | 25 | 0.140 |
Why?
|
| 3' Untranslated Regions | 2 | 2019 | 343 | 0.140 |
Why?
|
| Middle Aged | 21 | 2020 | 86204 | 0.140 |
Why?
|
| Carrier Proteins | 2 | 2014 | 2022 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2012 | 2307 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1225 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2016 | 167 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2013 | 4549 | 0.130 |
Why?
|
| Mice | 12 | 2019 | 34495 | 0.130 |
Why?
|
| Gene Expression | 1 | 2003 | 3570 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 3981 | 0.130 |
Why?
|
| Genomics | 2 | 2021 | 2738 | 0.130 |
Why?
|
| Neurons | 2 | 2005 | 2287 | 0.120 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 148 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7222 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2014 | 52 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 598 | 0.120 |
Why?
|
| Somatomedins | 1 | 1994 | 75 | 0.120 |
Why?
|
| Cell Survival | 3 | 2016 | 3045 | 0.120 |
Why?
|
| Comorbidity | 2 | 2020 | 2352 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 216 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 430 | 0.110 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 187 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2014 | 2370 | 0.110 |
Why?
|
| Epigenomics | 1 | 2014 | 266 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 799 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2013 | 316 | 0.110 |
Why?
|
| Genes, Insect | 2 | 2004 | 131 | 0.110 |
Why?
|
| Animals, Genetically Modified | 2 | 2004 | 406 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.110 |
Why?
|
| Adipogenesis | 1 | 2013 | 105 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 3890 | 0.100 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 392 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2014 | 311 | 0.100 |
Why?
|
| Protein Binding | 1 | 2018 | 3438 | 0.100 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2012 | 112 | 0.100 |
Why?
|
| Cell Movement | 2 | 2016 | 2466 | 0.100 |
Why?
|
| Osteogenesis | 1 | 2013 | 271 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 161 | 0.100 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 13658 | 0.100 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 29902 | 0.100 |
Why?
|
| Temperature | 2 | 2003 | 506 | 0.100 |
Why?
|
| Retrospective Studies | 11 | 2023 | 37905 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2001 | 2819 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 586 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2020 | 1330 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4143 | 0.100 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2011 | 236 | 0.100 |
Why?
|
| Proton Therapy | 2 | 2013 | 1577 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 598 | 0.090 |
Why?
|
| Neoplasms | 3 | 2014 | 15193 | 0.090 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 10001 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2013 | 9180 | 0.090 |
Why?
|
| Organs at Risk | 1 | 2013 | 514 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2054 | 0.090 |
Why?
|
| Genotype | 3 | 2009 | 4109 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 14889 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 1678 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 519 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 4988 | 0.090 |
Why?
|
| Repressor Proteins | 3 | 2004 | 1664 | 0.090 |
Why?
|
| Androgens | 1 | 2013 | 511 | 0.090 |
Why?
|
| Phenotype | 3 | 2008 | 6295 | 0.090 |
Why?
|
| Genome | 1 | 2013 | 672 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2009 | 76 | 0.090 |
Why?
|
| Liver | 2 | 2018 | 2961 | 0.090 |
Why?
|
| BRCA1 Protein | 1 | 2012 | 493 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 1362 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 629 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1489 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2019 | 11965 | 0.080 |
Why?
|
| Body Weight | 1 | 2013 | 1293 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 3 | 2012 | 4975 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2014 | 2084 | 0.080 |
Why?
|
| X Chromosome | 1 | 1989 | 339 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1989 | 290 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2004 | 1498 | 0.080 |
Why?
|
| Apoptosis | 3 | 2023 | 7591 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2014 | 8865 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2359 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1130 | 0.070 |
Why?
|
| Software | 1 | 2014 | 1321 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 2341 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 3343 | 0.070 |
Why?
|
| Genetics, Medical | 1 | 2007 | 143 | 0.070 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1026 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2013 | 6150 | 0.070 |
Why?
|
| Anthracyclines | 1 | 2008 | 331 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2019 | 32848 | 0.070 |
Why?
|
| Obesity | 1 | 2018 | 2884 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 1989 | 1471 | 0.070 |
Why?
|
| Databases, Genetic | 1 | 2008 | 745 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2004 | 1694 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 1077 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 7702 | 0.060 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2004 | 31 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2018 | 12873 | 0.060 |
Why?
|
| Adult | 10 | 2020 | 77950 | 0.060 |
Why?
|
| Genes, Switch | 1 | 2004 | 15 | 0.060 |
Why?
|
| 5' Flanking Region | 1 | 2004 | 21 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 6942 | 0.060 |
Why?
|
| Sucrose | 1 | 2004 | 64 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 5159 | 0.060 |
Why?
|
| Mifepristone | 1 | 2004 | 147 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 360 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2004 | 128 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 1213 | 0.060 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2004 | 220 | 0.060 |
Why?
|
| Time Factors | 2 | 2019 | 12926 | 0.060 |
Why?
|
| Larva | 1 | 2004 | 274 | 0.060 |
Why?
|
| 3T3-L1 Cells | 2 | 2013 | 77 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 289 | 0.060 |
Why?
|
| Female | 12 | 2023 | 141928 | 0.060 |
Why?
|
| Muscles | 1 | 2004 | 416 | 0.050 |
Why?
|
| Nerve Net | 1 | 2005 | 257 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5112 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2023 | 184 | 0.050 |
Why?
|
| Presenilin-1 | 1 | 2001 | 71 | 0.050 |
Why?
|
| Nitriles | 2 | 2019 | 906 | 0.050 |
Why?
|
| Radiometry | 2 | 2020 | 980 | 0.050 |
Why?
|
| DNA-Binding Proteins | 3 | 2016 | 4821 | 0.050 |
Why?
|
| Electroshock | 1 | 2001 | 46 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 694 | 0.050 |
Why?
|
| Afferent Pathways | 1 | 2001 | 64 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1972 | 0.050 |
Why?
|
| Dynamins | 1 | 2001 | 74 | 0.050 |
Why?
|
| Conditioning, Classical | 1 | 2001 | 69 | 0.050 |
Why?
|
| Risk Factors | 5 | 2020 | 17523 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 3578 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 305 | 0.050 |
Why?
|
| Mastectomy | 1 | 2007 | 1534 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2003 | 445 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 3552 | 0.050 |
Why?
|
| Mental Recall | 1 | 2001 | 171 | 0.050 |
Why?
|
| Urethra | 1 | 2020 | 144 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1070 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 1399 | 0.040 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2019 | 18 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2019 | 69 | 0.040 |
Why?
|
| NADP | 1 | 2019 | 96 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 127 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 71 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2001 | 336 | 0.040 |
Why?
|
| Nucleotides | 1 | 2019 | 164 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 3890 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 7551 | 0.040 |
Why?
|
| Kallikreins | 1 | 2019 | 84 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2008 | 6100 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 690 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4638 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 89 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2020 | 371 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 619 | 0.040 |
Why?
|
| Adipose Tissue, White | 1 | 2018 | 99 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 328 | 0.040 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2020 | 304 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2018 | 156 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 256 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 760 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 2 | 2013 | 902 | 0.040 |
Why?
|
| Lung | 1 | 2008 | 3151 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 5178 | 0.040 |
Why?
|
| Polyribosomes | 1 | 2016 | 34 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 241 | 0.040 |
Why?
|
| Nucleotide Motifs | 1 | 2016 | 62 | 0.040 |
Why?
|
| RNA, Small Nucleolar | 1 | 2016 | 25 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2014 | 9244 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Thymidine Kinase | 1 | 1996 | 193 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 478 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 348 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 1391 | 0.030 |
Why?
|
| Ascites | 1 | 1996 | 198 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 1082 | 0.030 |
Why?
|
| Receptors, Estrogen | 2 | 2011 | 2086 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 4844 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1997 | 359 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 2316 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 5377 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 3168 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2005 | 2967 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1997 | 494 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 246 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1994 | 60 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 652 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2001 | 855 | 0.030 |
Why?
|
| Sexuality | 1 | 2013 | 38 | 0.030 |
Why?
|
| Prognosis | 4 | 2018 | 21713 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2014 | 4307 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 40 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1832 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2013 | 152 | 0.030 |
Why?
|
| Testosterone Congeners | 1 | 2013 | 26 | 0.030 |
Why?
|
| Metribolone | 1 | 2013 | 48 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 973 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 716 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2013 | 214 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2012 | 44 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2014 | 421 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 169 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 726 | 0.030 |
Why?
|
| Dihydrotestosterone | 1 | 2012 | 118 | 0.030 |
Why?
|
| Bone Demineralization, Pathologic | 1 | 2011 | 4 | 0.030 |
Why?
|
| Germ Cells | 1 | 2014 | 335 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 915 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 1869 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2014 | 731 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 1997 | 1029 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 810 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 163 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2012 | 192 | 0.020 |
Why?
|
| Anilides | 1 | 2013 | 268 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 750 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2014 | 519 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 324 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 481 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2013 | 370 | 0.020 |
Why?
|
| Protein Stability | 1 | 2011 | 370 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Adenoviridae | 1 | 1996 | 1459 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 931 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1350 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1995 | 1152 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 644 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 629 | 0.020 |
Why?
|
| Weight Gain | 1 | 2013 | 464 | 0.020 |
Why?
|
| Cell Division | 1 | 1994 | 2489 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 4233 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1014 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1989 | 117 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 1989 | 128 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 14289 | 0.020 |
Why?
|
| DNA Probes | 1 | 1989 | 217 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 686 | 0.020 |
Why?
|
| United States | 2 | 2019 | 15433 | 0.020 |
Why?
|
| Gases | 1 | 2008 | 36 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1989 | 406 | 0.020 |
Why?
|
| Cause of Death | 1 | 2012 | 752 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 476 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 627 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2054 | 0.020 |
Why?
|
| NF-kappa B | 1 | 1995 | 1549 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 6089 | 0.020 |
Why?
|
| Survival Rate | 2 | 2012 | 12221 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 1392 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 5114 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5673 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 6682 | 0.020 |
Why?
|
| Cricetinae | 1 | 1989 | 706 | 0.020 |
Why?
|
| Brain | 1 | 2001 | 4113 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 803 | 0.020 |
Why?
|
| Genetic Privacy | 1 | 2007 | 40 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.020 |
Why?
|
| Diaphragm | 1 | 2008 | 181 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 1084 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 3536 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 1466 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2508 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.020 |
Why?
|
| DNA | 1 | 2014 | 2693 | 0.020 |
Why?
|
| Stomach | 1 | 2008 | 387 | 0.020 |
Why?
|
| Premenopause | 1 | 2005 | 131 | 0.020 |
Why?
|
| Movement | 1 | 2008 | 556 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4298 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2008 | 690 | 0.020 |
Why?
|
| Forecasting | 1 | 2007 | 694 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1859 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3154 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 2483 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5637 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 4804 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6009 | 0.010 |
Why?
|
| Heart | 1 | 2008 | 1223 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4078 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3719 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 6311 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1997 | 5395 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 6869 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2007 | 1589 | 0.010 |
Why?
|
| Isopropyl Thiogalactoside | 1 | 1997 | 6 | 0.010 |
Why?
|
| Lac Repressors | 1 | 1997 | 14 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6207 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1996 | 121 | 0.010 |
Why?
|
| Luciferases | 1 | 1997 | 445 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1996 | 56 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1996 | 69 | 0.010 |
Why?
|
| Ganciclovir | 1 | 1996 | 174 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1996 | 159 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1995 | 211 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 1995 | 184 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1997 | 1519 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1997 | 1764 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 997 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 694 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1995 | 1258 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1996 | 2314 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 2171 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 21445 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1995 | 1732 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 2927 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1995 | 1203 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 31252 | 0.010 |
Why?
|